MannKind Corporation (MNKD)
NASDAQ: MNKD · Real-Time Price · USD
4.140
+0.210 (5.34%)
At close: Jun 26, 2026, 4:00 PM EDT
4.110
-0.030 (-0.72%)
After-hours: Jun 26, 2026, 7:59 PM EDT
MannKind Employees
As of December 31, 2025, MannKind had 592 total employees, including 591 full-time and 1 part-time employees. The number of employees increased by 185 or 45.45% compared to the previous year.
Employees
592
Change (1Y)
185
Growth (1Y)
45.45%
Revenue / Employee
$609,431
Profits / Employee
-$40,395
Market Cap
1.28B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Ascentage Pharma Group International | 767 |
| Novavax | 749 |
| Immatics | 678 |
| Wave Life Sciences | 317 |
| Xencor | 260 |
| EyePoint | 214 |
| Inhibrx Biosciences | 110 |
| Cullinan Therapeutics | 109 |
MNKD News
- 3 days ago - MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D - GlobeNewsWire
- 21 days ago - Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind's Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems - GlobeNewsWire
- 23 days ago - MannKind Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 24 days ago - MannKind announces milestones in development of nintedanib DPI for IPF - TheFly
- 24 days ago - MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF - GlobeNewsWire
- 26 days ago - MannKind price target raised to $11 from $10 at Wells Fargo - TheFly
- 4 weeks ago - MannKind Transcript: FDA announcement - Transcripts
- 4 weeks ago - MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval - GlobeNewsWire